BioSpace News Archive

Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced that four scientific presentations have been accepted at the upcoming American Society of Nephrology (ASN) Kidney Week (November 3-6, 2022) taking place in Orlando, Florida.

Decibel Therapeutics today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to initiate a Phase 1/2 clinical trial in pediatric patients of DB-OTO, its lead gene therapy product candidate. DB-OTO is designed to provide durable hearing in individuals born with profound congenital hearing loss due to an otoferlin deficiency.

Kira Pharmaceuticals, today announced it will present data from its Phase 1 SYNERGY-1 trial of lead candidate KP104 at the American Society of Nephrology (ASN) Kidney Week 2022, occurring November 3-6 in Orlando, FL.

Enanta Pharmaceuticals, Inc today announced that it has dosed the first subject in its Phase 1 clinical trial of EDP-323, a novel, oral L-protein inhibitor in development for the treatment of respiratory syncytial virus (RSV).

Cardiovascular Systems, Inc. announced today the full market release of the 2.00 Max Crown for Peripheral Orbital Atherectomy Systems (2.00 Max Crown).

Toronto Innovation Acceleration Partners (“TIAP”) and Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that the two companies have expanded LAB150, their translational BRIDGE partnership, to include Amgen as a strategic partner.

Nutriband Inc. today announced that it has accepted an invitation as a guest speaker for the 2023 Transdermal and Microneedle Conference to be held in London on January 23 and 24.

M2GEN, a bioinformatics company accelerating discoveries in oncology research through industry-leading data and analytics, today announced the appointment of Kyle Dunn to its executive team as Chief Revenue Officer.

NGM Biopharmaceuticals, Inc. today announced topline efficacy and safety results from its randomized, double-masked, sham-controlled CATALINA Phase 2 trial of NGM621 in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Gilead Sciences, Inc. (NASDAQ: GILD) and MacroGenics (NASDAQ: MGNX) today announced an exclusive option and collaboration agreement to develop MGD024, an investigational, bispecific research programs.